Diamedica Therapeutics (DMAC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Diamedica Therapeutics Inc. has filed a Form 8-K with the SEC, detailing a current report that could impact its stock, traded under the symbol DMAC on The Nasdaq Stock Market LLC. The report, dated May 8, 2024, pertains to the company, headquartered in Minneapolis, Minnesota, which is not classified as an emerging growth company.
For further insights into DMAC stock, check out TipRanks’ Stock Analysis page.
